Another Day, Another Big Pharma Breakup

In this video from Thursday's Market Checkup, Motley Fool health -are analyst David Williamson discusses a number of pharmaceutical companies that have aggressively reshaped themselves recently to deal with the effects of a looming patent cliff. Now, it seems that Merck (NYSE: MRK  ) may be on the verge of making a similar move. It is rumored that the company's consumer unit may be up for sale, and with such brands as Dr. Scholl's, Claritin, and Coppertone under that umbrella, the news is understandably generating a lot of interest. The potential sale is expected to raise roughly $11 billion

In this segment, David discusses the details of the potential deal, as well as just how far that $11 billion would go in restocking Merck's pipeline. David then takes a look at that pipeline and discusses some of its underrated potential blockbuster candidates.

The secret to investing in biotech stocks
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In The Motley Fool's brand-new free report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2858598, ~/Articles/ArticleHandler.aspx, 7/29/2014 11:07:00 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement